Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | (6,207) | (5,254) | (12,567) | (15,444) |
| Income tax expense (benefit) | 3,141 | (43,254) | 15,356 | 20,736 |
| Depreciation and amortization expense | 10,409 | 10,840 | 21,003 | 20,818 |
| Stock-based compensation expense | 24,472 | 37,025 | 53,871 | 78,453 |
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Segment net (loss) income | $(4,890) | $196,892 | $326,069 | $(250,616) |
| Reconciliation of profit or loss | ||||
| Adjustments and reconciling items | — | — | — | — |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — stock-based comp?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — stock-based comp of $24.47M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — stock-based comp changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — stock-based comp decreased by 33.9% year-over-year, from $37.03M to $24.47M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — stock-based comp has grown at a -19.1% compound annual growth rate (CAGR), from $233.02M to $123.4M.
- What does business segments — stock-based comp mean?
- The expense recognized for equity-based awards granted to employees and personnel within the segment. This non-cash charge reflects the cost of aligning employee incentives with shareholder interests. It is a critical component of total personnel costs and impacts the segment's reported operating margins.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude